Docoh
Loading...

139 results

Filter options loading...
Top filers
Top filing types
Recent filing years
10-Q
2021 Q2
EX-31.1
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing equivalent
10-Q
2021 Q2
EX-31.2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing equivalent
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
; Payments Books and Reconrds; Audit Rights Tax Matters Payment Method and Currency Conversion Blocked Payments Late Payments ARTICLE VII INTELLECTUAL … Report, Processa shall pay to Ocuphire all amounts payable by it under Section 6.5 and 6.6. 6.8 Books and Records; Audit Rights. Processa shall keep
10-Q
2021 Q1
EX-31.1
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board
10-Q
2021 Q1
EX-31.2
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board
DEF 14A
fye3gzt 9ovofkc38
22 Apr 21
Definitive proxy
2:00pm
10-K/A
7w6m9amc n6ln
7 Apr 21
Annual report (amended)
4:23pm
10-K
EX-31.2
a4ycsp
24 Mar 21
Annual report
8:00pm
10-K
EX-31.1
eoizlvqhxh jw82c
24 Mar 21
Annual report
8:00pm
10-K
otgd9gcwt3kxi87gctu
24 Mar 21
Annual report
8:00pm
8-K
EX-10.1
hy5o 6pqos5tkknvu
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-10.2
udaot39f80km81xd
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
10-Q
EX-31.1
q7nudwkq
12 Nov 20
Quarterly report
4:01pm
10-Q
EX-31.2
g880fq0apcxrybzwns
12 Nov 20
Quarterly report
4:01pm
8-K
EX-1.1
gqisf4 7j
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
cya2d1jnxm
5 Oct 20
Prospectus supplement with pricing info
4:16pm
S-1/A
icok0a08
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
EX-23.2
7hig3lxk6zdotcgwjj
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
xf7bl759r
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-2.1
qf9bkk69q12z 8le5
16 Sep 20
IPO registration (amended)
8:00pm